Prime medicine presents first in vivo proof-of-concept prime editing data demonstrating ability of prime editors to treat ophthalmological diseases

New in vivo data in humanized mouse model demonstrate that prime editing can correct predominant mutations accounting for approximately 60% of patients with rho adrp up to 70% precise correction at rho p.p23h mutation and up to 65% at rho p.v345l and p.p347l, well above threshold required to stop disease progression in photoreceptors no detectable aav genome integration and no detectable off-target edits observed data presented today in an oral presentation at rd2023 cambridge, mass., oct. 24, 2023 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of prime editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (rho adrp).
PRME Ratings Summary
PRME Quant Ranking